SK-RC-(M): Metastatic Human Renal Cell Carcinoma (RCC) Cell Line Collection

Share

Description

This is a collection of renal cell carcinoma (RCC) cell lines derived from metastatic sites of patients who underwent surgery. See chart for additional information.

Metastatic Human Renal Cell Carcinoma Cell Line Collection

Cell Line Metastatic Site Growth in Nude Mice Growth in Soft Agar
SK-RC-9 Brain No Yes
SK-RC-13 * Brain Yes No
SK-RC-17 Soft Tissue Not Determined Yes
SK-RC-18 Lymph Node Yes Yes
SK-RC-26a * Lung Not Determined Not Determined
SK-RC-26b * Lymph Node Not Determined Not Determined
SK-RC-29 Ovary Yes Yes
SK-RC-31 Lung Yes Yes
SK-RC-38 Lung Yes Yes
SK-RC-39 Soft Tissue Yes Yes
SK-RC-42 Bone Yes Yes
SK-RC-45* Adrenal Gland Yes Yes
SK-RC-46 Bone Not Determined No
SK-RC-52 Mediastinum Yes Yes
SK-RC-54 Lung Not Determined Not Determined

*A cell line established from the primary tumor of the same patient is available.

Adapted from Ebert T et al. Cancer Research 50: 5531-5536 (1990)

Source

All cell lines were established in Dr. Lloyd Old’s laboratory, from patients undergoing nephrectomy at Memorial Hospital, Memorial Sloan Kettering Cancer Center, between the years 1972 and 1987. Fresh surgical specimens were obtained from Tumor Procurement Services, Department of Surgical Pathology, Memorial Hospital, Memorial Sloan Kettering.

Inventors

Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research, and members of the Old Laboratory

Key References

  • Ueda R et al. (1979) Cell surface antigens of human renal cancer defined by autologous typing. Journal of Experimental Medicine 150: 564-579 (PubMed ID: 479762)
  • Ebert T et al. (1990) Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Research 50: 5531-5536 (PubMed ID: 2386958)
  • Sjölund J et al. (2008) Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. Journal of Clinical Investigation 118: 217-228 (PubMed ID: 18079963)

Licensing Information

These cell lines may be nonexclusively licensed, individually or in any preferred combination, for research or commercial purposes.

Contact Information

  • For licensing requests: please contact [email protected].
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected]

Stage of Development

Ready to use

Indications